Glycine Peptide

Glycine (aminoacetic acid) is the simplest proteinogenic amino acid and a major inhibitory neurotransmitter in the spinal cord and brainstem, acting at strychnine-sensitive glycine receptors (GlyRs). Its sleep-promoting properties, however, appear to arise through a pharmacologically distinct pathway: activation of N-methyl-D-aspartate (NMDA) glutamate receptors within the suprachiasmatic nucleus (SCN), the brain's master circadian pacemaker.

When oral glycine enters systemic circulation, it reaches the SCN and activates NMDA receptor complexes located there. In rat models studied by Kawai et al. (2015, Neuropsychopharmacology; PMID 25533534), this SCN activation triggers downstream peripheral vasodilation, increasing cutaneous blood flow particularly at the plantar surfaces. The resultant heat dissipation lowers core body temperature, replicating the physiological cooling that normally precedes and facilitates sleep onset. The researchers confirmed the mechanism by demonstrating that NMDA receptor antagonists (AP5 and CGP78608) blocked the effect while the GlyR antagonist strychnine did not, and that complete SCN ablation abolished both the hypothermic and sleep-promoting effects entirely.

Glycine also modulates neuropeptide expression within the SCN, increasing arginine vasopressin (AVP) and vasoactive intestinal polypeptide (VIP) during the light phase, suggesting additional circadian regulatory influence beyond thermoregulation alone. Notably, glycine does not appear to alter plasma melatonin concentrations or canonical circadian clock gene expression (Bmal1, Per2), distinguishing it mechanistically from melatonin-based sleep interventions.

Human evidence for glycine and sleep rests on a small number of published trials, all using an oral dose of 3 g before bedtime.

The most frequently cited human study is Yamadera et al. (2007, Sleep and Biological Rhythms; DOI 10.1111/j.1479-8425.2007.00262.x), a crossover trial in volunteers reporting consistently poor sleep quality. Polysomnographic recording showed significant shortening of latency to sleep onset and latency to slow-wave sleep (SWS) in the glycine condition. Subjective sleep quality and sleep efficacy improved, next-day alertness increased, and performance on memory recognition tasks was enhanced. Total sleep time and overall sleep stage architecture were not significantly altered.

Bannai et al. (2012, Frontiers in Neurology; PMID 22529837) enrolled 7 healthy adult males in a randomized single-blind crossover design in which sleep was restricted to approximately 25% below baseline (roughly 5.5 h per night for three consecutive nights). Participants receiving 3 g glycine 30 minutes before bedtime demonstrated significant improvement in psychomotor vigilance test reaction time on days 1 and 3, and a significant reduction in fatigue ratings on day 1 (p = 0.022). Plasma melatonin concentrations and circadian clock gene expression were unaffected, consistent with the non-melatonin mechanism.

Thomas et al. (2023, British Journal of Nutrition; PMID 37874350) examined collagen peptides (15 g per day, containing approximately 3.5 g glycine) versus placebo in 13 physically active males with sleep complaints, using a randomized double-blind crossover design over 7 nights. Polysomnography revealed significantly fewer awakenings with collagen peptides than placebo (21.3 +/- 9.7 vs. 29.3 +/- 13.8 counts; p = 0.028). Cognitive performance (Stroop test correct responses) was also superior. Sleep latency, efficiency, and stage architecture did not differ significantly, suggesting a benefit to sleep continuity rather than initiation or total duration.

All published human trials are small (n = 7 to 13). A substantive limitation is that key early studies involve authors with affiliations to Ajinomoto Co., a major global glycine manufacturer, introducing potential conflicts of interest. No large-scale, independently funded RCTs have been published.

Typical dosage: 3-5 g (before bed).

All published human sleep trials used a single oral dose of 3 g of glycine taken approximately 30 to 60 minutes before bedtime. This dose was administered as an aqueous solution in the Bannai and Yamadera studies. Commercial preparations include capsules, tablets, and flavored powders dissolved in water, though none of these specific delivery forms have been directly compared in sleep-focused clinical trials.

Higher doses have been investigated in other contexts: 0.4 to 0.8 g per kilogram of body weight daily (roughly 28 to 56 g per day for a 70 kg individual), given in divided doses, has been used as adjunctive treatment for negative symptoms of schizophrenia (Heresco-Levy et al., JAMA Psychiatry 1999). These high-dose regimens were generally tolerated, though transient gastrointestinal complaints were reported.

For sleep applications, no minimum effective dose has been established, and doses below 3 g lack published efficacy data. Some commercial sleep supplements provide 1 to 2 g per serving; evidence supporting benefit at these lower amounts is absent from the peer-reviewed literature.

This information is provided for educational purposes only and is not intended as medical advice. Individuals considering glycine supplementation — particularly those with kidney or liver disease, those taking prescription medications such as clozapine, or those who are pregnant or breastfeeding — should consult a qualified healthcare professional before use.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

Collagen peptides represent the best-studied vehicle delivering glycine in a sleep context. Glycine constitutes approximately 20 to 25% of collagen's amino acid composition by mass; a 15 g collagen peptide serving delivers roughly 3 to 3.5 g of glycine alongside proline, hydroxyproline, and other amino acids. The Thomas et al. (2023) crossover trial is the primary human evidence base for this approach, demonstrating reduced sleep awakenings in physically active males. Whether the effects observed are attributable to glycine alone, to the full collagen peptide matrix, or to both cannot be determined from that study.

Magnesium is frequently co-formulated with glycine in consumer sleep products. The chelated form magnesium bisglycinate provides both minerals simultaneously. A 2024 randomized placebo-controlled trial published in the journal Nature and Science of Sleep examined magnesium bisglycinate supplementation in healthy adults reporting poor sleep and found improvements in several sleep parameters; however, the study did not isolate the contribution of glycine from that of magnesium, so the combination's synergy remains unproven. Rationale for combining is that both have proposed complementary sleep-support mechanisms (thermoregulation for glycine; GABAergic and melatonin-pathway modulation for magnesium), but evidence specifically attributing benefit to the combined use versus either ingredient alone is absent.

L-theanine appears alongside glycine in several commercial sleep formulations. L-theanine has independent anxiolytic and sleep-support evidence in small trials, but no clinical study has examined glycine plus L-theanine specifically for sleep. Any claims for this pairing are anecdotal.

Glycine Peptide is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Very safe

At the 3 g dose used in published sleep research, no adverse effects were documented. The most commonly reported side effects at higher doses are nausea, vomiting, and stomach upset; these gastrointestinal effects are dose-dependent and more likely above 10 to 15 g per day. In the schizophrenia adjunct literature, doses of approximately 30 g per day were associated with transient GI complaints in some participants but no serious adverse events.

Because glycine is a non-essential amino acid synthesized endogenously and present throughout dietary protein sources, its safety profile at supplemental sleep doses is considered favorable. No dependency, tolerance development, rebound insomnia, next-day sedation, or cognitive impairment has been reported in sleep trials. This contrasts with benzodiazepines and z-drugs, which carry known dependency and next-day impairment risks.

One clinically meaningful drug interaction has been identified: high-dose glycine may reduce the therapeutic effectiveness of clozapine (Clozaril), an atypical antipsychotic used for treatment-resistant schizophrenia. The mechanism is not fully established, and co-administration is generally discouraged. No interactions have been documented at 3 g for other medications, but evidence is limited by small trial sizes.

Glycine supplementation during pregnancy and breastfeeding is not recommended due to insufficient safety data. Individuals with impaired renal or hepatic function should use caution because glycine is metabolized through both pathways. No regulatory body has established a maximum safe supplemental dose for healthy adults; however, glycine is recognized by the U.S. FDA as a permitted food additive under specific use conditions (21 CFR 170.50), reflecting an established safety profile at food-use levels.